Adam Brufsky, MD - Episode 4

CDK4/6 Inhibitors for HR+ Breast Cancer; Emergence of Ribociclib

EP. 1: Neratinib in the Adjuvant Setting The Paradigm Shift for HER2+ Breast Cancer Neratinib Toxicity Management
EP. 2: Neratinib for Metastatic Breast Cancer
EP. 3: Personal Experience with Neratinib
Now Viewing
EP. 4: CDK4/6 Inhibitors for HR+ Breast Cancer; Emergence of Ribociclib
EP. 5: Sequencing Therapies for HR+ Metastatic Breast Cancer

Related Content:

Adam Brufsky, MD
Sequencing Therapies for HR+ Metastatic Breast Cancer
Personal Experience with Neratinib
Neratinib for Metastatic Breast Cancer